C
NexgenRx Inc.
NXG.V
TSX
C
Hold
12/2/2024Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 12/2/2024 due to a decline in the volatility index, valuation index and dividend index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 12/2/2024 due to a decline in the volatility index, valuation index and dividend index.
C
Hold
11/15/2024Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 11/15/2024 due to an increase in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 11/15/2024 due to an increase in the total return index and volatility index.
C
Hold
10/24/2024Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 10/24/2024 due to a decline in the valuation index, volatility index and dividend index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 10/24/2024 due to a decline in the valuation index, volatility index and dividend index.
C
Hold
10/9/2024Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 10/9/2024 due to an increase in the volatility index and total return index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 10/9/2024 due to an increase in the volatility index and total return index.
C
Hold
9/24/2024Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 9/24/2024 due to a decline in the volatility index and total return index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 9/24/2024 due to a decline in the volatility index and total return index.
C
Hold
8/22/2024Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 8/22/2024 due to an increase in the dividend index, volatility index and valuation index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 8/22/2024 due to an increase in the dividend index, volatility index and valuation index.
C
Hold
6/21/2024Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 6/21/2024 due to a significant increase in the growth index, volatility index and total return index. EBIT increased 291.96% from -$185.3 to $355.7, earnings per share increased from -$0.0042 to $0.0045, and total revenue increased 21.21% from $2.63M to $3.18M.
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 6/21/2024 due to a significant increase in the growth index, volatility index and total return index. EBIT increased 291.96% from -$185.3 to $355.7, earnings per share increased from -$0.0042 to $0.0045, and total revenue increased 21.21% from $2.63M to $3.18M.
D
Sell
4/11/2024Upgraded
NexgenRx Inc. (NXG.V) was upgraded to D+ from D on 4/11/2024 due to an increase in the dividend index, efficiency index and growth index. Total revenue increased 3.93% from $2.53M to $2.63M.
NexgenRx Inc. (NXG.V) was upgraded to D+ from D on 4/11/2024 due to an increase in the dividend index, efficiency index and growth index. Total revenue increased 3.93% from $2.53M to $2.63M.
D
Sell
2/16/2024Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D from D+ on 2/16/2024 due to a noticeable decline in the efficiency index, total return index and dividend index. Net income declined 1,423.44% from -$6.4 to -$97.5, and total capital declined 3.23% from $6.81M to $6.59M.
NexgenRx Inc. (NXG.V) was downgraded to D from D+ on 2/16/2024 due to a noticeable decline in the efficiency index, total return index and dividend index. Net income declined 1,423.44% from -$6.4 to -$97.5, and total capital declined 3.23% from $6.81M to $6.59M.
D
Sell
11/10/2023Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 11/10/2023 due to a noticeable decline in the volatility index, growth index and total return index. Earnings per share declined from $0.002 to -$0.0001, EBIT declined 95.99% from $157.3 to $6.3, and total revenue declined 0.33% from $2.56M to $2.55M.
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 11/10/2023 due to a noticeable decline in the volatility index, growth index and total return index. Earnings per share declined from $0.002 to -$0.0001, EBIT declined 95.99% from $157.3 to $6.3, and total revenue declined 0.33% from $2.56M to $2.55M.
C
Hold
8/1/2023Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 8/1/2023 due to an increase in the valuation index.
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 8/1/2023 due to an increase in the valuation index.
D
Sell
7/6/2023Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 7/6/2023 due to a decline in the total return index, efficiency index and volatility index.
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 7/6/2023 due to a decline in the total return index, efficiency index and volatility index.
C
Hold
4/10/2023Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 4/10/2023 due to a significant decline in the valuation index, dividend index and growth index. Earnings per share declined from -$0.0008 to -$0.0039, EBIT declined 349.53% from -$21.2 to -$95.3, and operating cash flow declined 136.05% from $988.6 to -$356.4.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 4/10/2023 due to a significant decline in the valuation index, dividend index and growth index. Earnings per share declined from -$0.0008 to -$0.0039, EBIT declined 349.53% from -$21.2 to -$95.3, and operating cash flow declined 136.05% from $988.6 to -$356.4.
C
Hold
1/4/2023Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 1/4/2023 due to an increase in the volatility index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 1/4/2023 due to an increase in the volatility index.
C
Hold
12/19/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 12/19/2022 due to a noticeable decline in the volatility index, valuation index and solvency index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 12/19/2022 due to a noticeable decline in the volatility index, valuation index and solvency index.
C
Hold
11/17/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 11/17/2022 due to an increase in the volatility index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 11/17/2022 due to an increase in the volatility index.
C
Hold
11/2/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 11/2/2022 due to a significant decline in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 11/2/2022 due to a significant decline in the total return index and volatility index.
C
Hold
8/19/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C from B on 8/19/2022 due to a significant decline in the growth index, dividend index and valuation index. Earnings per share declined from $0.0039 to -$0.0004, EBIT declined 87.6% from $312 to $38.7, and total revenue declined 2.63% from $2.51M to $2.44M.
NexgenRx Inc. (NXG.V) was downgraded to C from B on 8/19/2022 due to a significant decline in the growth index, dividend index and valuation index. Earnings per share declined from $0.0039 to -$0.0004, EBIT declined 87.6% from $312 to $38.7, and total revenue declined 2.63% from $2.51M to $2.44M.
B
Buy
8/17/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 8/17/2022 due to a substantial increase in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 8/17/2022 due to a substantial increase in the total return index and volatility index.
B
Buy
7/25/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 7/25/2022 due to a major increase in the total return index and valuation index.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 7/25/2022 due to a major increase in the total return index and valuation index.
C
Hold
7/8/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 7/8/2022 due to a decline in the total return index, valuation index and dividend index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 7/8/2022 due to a decline in the total return index, valuation index and dividend index.
B
Buy
6/23/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 6/23/2022 due to an increase in the total return index.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 6/23/2022 due to an increase in the total return index.
C
Hold
6/7/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 6/7/2022 due to a decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 6/7/2022 due to a decline in the total return index.
B
Buy
5/23/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 5/23/2022 due to an increase in the dividend index.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 5/23/2022 due to an increase in the dividend index.
C
Hold
4/18/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 4/18/2022 due to a decline in the volatility index and valuation index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 4/18/2022 due to a decline in the volatility index and valuation index.
B
Buy
3/25/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 3/25/2022 due to a large increase in the valuation index, growth index and solvency index. Operating cash flow increased 1,931.13% from $89.3 to $1.81M, earnings per share increased from $0.0048 to $0.0304, and EBIT increased 121.48% from $349.1 to $773.2.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 3/25/2022 due to a large increase in the valuation index, growth index and solvency index. Operating cash flow increased 1,931.13% from $89.3 to $1.81M, earnings per share increased from $0.0048 to $0.0304, and EBIT increased 121.48% from $349.1 to $773.2.
C
Hold
3/15/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 3/15/2022 due to a decline in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 3/15/2022 due to a decline in the total return index and volatility index.
B
Buy
2/24/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 2/24/2022 due to an increase in the total return index, valuation index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 2/24/2022 due to an increase in the total return index, valuation index and volatility index.
C
Hold
2/8/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B on 2/8/2022 due to a significant decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B on 2/8/2022 due to a significant decline in the total return index.
B
Buy
1/28/2022Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 1/28/2022 due to an increase in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 1/28/2022 due to an increase in the total return index and volatility index.
B
Buy
1/13/2022Downgrade
NexgenRx Inc. (NXG.V) was downgraded to B- from B on 1/13/2022 due to a noticeable decline in the total return index and valuation index.
NexgenRx Inc. (NXG.V) was downgraded to B- from B on 1/13/2022 due to a noticeable decline in the total return index and valuation index.
B
Buy
12/28/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B from C+ on 12/28/2021 due to a significant increase in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to B from C+ on 12/28/2021 due to a significant increase in the total return index and volatility index.
C
Hold
12/16/2021Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B on 12/16/2021 due to a significant decline in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B on 12/16/2021 due to a significant decline in the total return index and volatility index.
B
Buy
12/8/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 12/8/2021 due to a large increase in the total return index, volatility index and valuation index.
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 12/8/2021 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
11/22/2021Downgrade
NexgenRx Inc. (NXG.V) was downgraded to B- from B on 11/22/2021 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 88.66% from $787.6 to $89.3.
NexgenRx Inc. (NXG.V) was downgraded to B- from B on 11/22/2021 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 88.66% from $787.6 to $89.3.
B
Buy
11/8/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 11/8/2021 due to a large increase in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to B from B- on 11/8/2021 due to a large increase in the total return index and volatility index.
B
Buy
8/19/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 8/19/2021 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 122.26% from $354.4 to $787.7, earnings per share increased from $0.0037 to $0.0041, and net income increased 8.22% from $286 to $309.5.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 8/19/2021 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 122.26% from $354.4 to $787.7, earnings per share increased from $0.0037 to $0.0041, and net income increased 8.22% from $286 to $309.5.
C
Hold
8/17/2021Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 8/17/2021 due to a large decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 8/17/2021 due to a large decline in the total return index.
B
Buy
8/2/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 8/2/2021 due to an increase in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 8/2/2021 due to an increase in the total return index and volatility index.
C
Hold
7/15/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C+ from C on 7/15/2021 due to a substantial increase in the total return index.
NexgenRx Inc. (NXG.V) was upgraded to C+ from C on 7/15/2021 due to a substantial increase in the total return index.
C
Hold
6/30/2021Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C from C+ on 6/30/2021 due to a substantial decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to C from C+ on 6/30/2021 due to a substantial decline in the total return index.
C
Hold
5/27/2021Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 5/27/2021 due to a large decline in the growth index. Earnings per share declined from $0.0085 to $0.004, and operating cash flow declined 49.18% from $697.3 to $354.4.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 5/27/2021 due to a large decline in the growth index. Earnings per share declined from $0.0085 to $0.004, and operating cash flow declined 49.18% from $697.3 to $354.4.
B
Buy
5/11/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 5/11/2021 due to a major increase in the total return index and efficiency index.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 5/11/2021 due to a major increase in the total return index and efficiency index.
C
Hold
4/26/2021Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 4/26/2021 due to a large decline in the total return index and valuation index.
NexgenRx Inc. (NXG.V) was downgraded to C+ from B- on 4/26/2021 due to a large decline in the total return index and valuation index.
B
Buy
4/7/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 4/7/2021 due to a substantial increase in the total return index.
NexgenRx Inc. (NXG.V) was upgraded to B- from C+ on 4/7/2021 due to a substantial increase in the total return index.
C
Hold
4/5/2021Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C+ from C on 4/5/2021 due to a major increase in the total return index, growth index and efficiency index. Net income increased 68.83% from $382.7 to $646.1, earnings per share increased from $0.0053 to $0.0089, and operating cash flow increased 59.46% from $437.3 to $697.3.
NexgenRx Inc. (NXG.V) was upgraded to C+ from C on 4/5/2021 due to a major increase in the total return index, growth index and efficiency index. Net income increased 68.83% from $382.7 to $646.1, earnings per share increased from $0.0053 to $0.0089, and operating cash flow increased 59.46% from $437.3 to $697.3.
C
Hold
12/4/2020Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 12/4/2020 due to an increase in the volatility index and total return index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 12/4/2020 due to an increase in the volatility index and total return index.
C
Hold
11/20/2020Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 11/20/2020 due to a significant increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 1.13 to 0.38, net income increased 10.64% from $345.9 to $382.7, and total capital increased 6.82% from $4.59M to $4.9M.
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 11/20/2020 due to a significant increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 1.13 to 0.38, net income increased 10.64% from $345.9 to $382.7, and total capital increased 6.82% from $4.59M to $4.9M.
D
Sell
11/4/2020Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 11/4/2020 due to a decline in the volatility index, valuation index and total return index.
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 11/4/2020 due to a decline in the volatility index, valuation index and total return index.
C
Hold
10/20/2020Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 10/20/2020 due to an increase in the volatility index.
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 10/20/2020 due to an increase in the volatility index.
D
Sell
9/8/2020Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 9/8/2020 due to a decline in the volatility index and total return index.
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 9/8/2020 due to a decline in the volatility index and total return index.
C
Hold
8/21/2020Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D on 8/21/2020 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.003 to $0.0051, operating cash flow increased 67.37% from $317.2 to $530.9, and net income increased 63.31% from $211.8 to $345.9.
NexgenRx Inc. (NXG.V) was upgraded to C- from D on 8/21/2020 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.003 to $0.0051, operating cash flow increased 67.37% from $317.2 to $530.9, and net income increased 63.31% from $211.8 to $345.9.
D
Sell
8/27/2019Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D from D+ on 8/27/2019 due to a noticeable decline in the growth index, efficiency index and volatility index. Earnings per share declined from $0.0012 to -$0.0004, net income declined 132.14% from $81.2 to -$26.1, and EBIT declined 87.72% from $120.5 to $14.8.
NexgenRx Inc. (NXG.V) was downgraded to D from D+ on 8/27/2019 due to a noticeable decline in the growth index, efficiency index and volatility index. Earnings per share declined from $0.0012 to -$0.0004, net income declined 132.14% from $81.2 to -$26.1, and EBIT declined 87.72% from $120.5 to $14.8.
D
Sell
5/15/2019Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 5/15/2019 due to a decline in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 5/15/2019 due to a decline in the total return index and volatility index.
C
Hold
4/24/2019Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 4/24/2019 due to a large decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 4/24/2019 due to a large decline in the total return index.
C
Hold
4/9/2019Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 4/9/2019 due to a large increase in the growth index, efficiency index and total return index. Operating cash flow increased 254.55% from -$193.6 to $299.2, EBIT increased 171.62% from -$292.1 to $209.2, and net income increased 145.17% from -$308.8 to $139.5.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 4/9/2019 due to a large increase in the growth index, efficiency index and total return index. Operating cash flow increased 254.55% from -$193.6 to $299.2, EBIT increased 171.62% from -$292.1 to $209.2, and net income increased 145.17% from -$308.8 to $139.5.
C
Hold
12/3/2018Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 12/3/2018 due to an increase in the total return index.
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 12/3/2018 due to an increase in the total return index.
D
Sell
11/29/2018Upgraded
NexgenRx Inc. (NXG.V) was upgraded to D+ from D on 11/29/2018 due to a large increase in the efficiency index, growth index and volatility index. Total capital increased 162.17% from $1.49M to $3.91M, and total revenue increased 12.99% from $1.12M to $1.27M.
NexgenRx Inc. (NXG.V) was upgraded to D+ from D on 11/29/2018 due to a large increase in the efficiency index, growth index and volatility index. Total capital increased 162.17% from $1.49M to $3.91M, and total revenue increased 12.99% from $1.12M to $1.27M.
D
Sell
3/23/2018Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D from C- on 3/23/2018 due to a major decline in the growth index, efficiency index and volatility index. Operating cash flow declined 257.11% from $121 to -$190.1, net income declined 148.35% from -$121 to -$300.5, and EBIT declined 137.42% from -$111.7 to -$265.2.
NexgenRx Inc. (NXG.V) was downgraded to D from C- on 3/23/2018 due to a major decline in the growth index, efficiency index and volatility index. Operating cash flow declined 257.11% from $121 to -$190.1, net income declined 148.35% from -$121 to -$300.5, and EBIT declined 137.42% from -$111.7 to -$265.2.
C
Hold
3/13/2018Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 3/13/2018 due to a noticeable increase in the total return index.
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 3/13/2018 due to a noticeable increase in the total return index.
D
Sell
2/26/2018Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 2/26/2018 due to a major decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 2/26/2018 due to a major decline in the total return index.
C
Hold
12/20/2017Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 12/20/2017 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 833.33% from -$16.5 to $121, and total revenue increased 4% from $1.06M to $1.11M.
NexgenRx Inc. (NXG.V) was upgraded to C- from D+ on 12/20/2017 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 833.33% from -$16.5 to $121, and total revenue increased 4% from $1.06M to $1.11M.
D
Sell
7/26/2017Downgrade
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 7/26/2017 due to a decline in the volatility index and total return index.
NexgenRx Inc. (NXG.V) was downgraded to D+ from C- on 7/26/2017 due to a decline in the volatility index and total return index.
C
Hold
6/13/2017Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 6/13/2017 due to a significant decline in the total return index, efficiency index and growth index. Operating cash flow declined 143.13% from $257.6 to -$111.1, earnings per share declined from $0.0052 to $0.0002, and net income declined 95.92% from $316.3 to $12.9.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 6/13/2017 due to a significant decline in the total return index, efficiency index and growth index. Operating cash flow declined 143.13% from $257.6 to -$111.1, earnings per share declined from $0.0052 to $0.0002, and net income declined 95.92% from $316.3 to $12.9.
C
Hold
3/31/2017Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 3/31/2017 due to a significant increase in the efficiency index, growth index and solvency index. Net income increased 1,344.29% from $21.9 to $316.3, earnings per share increased from $0.0004 to $0.0054, and operating cash flow increased 955.74% from $24.4 to $257.6.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 3/31/2017 due to a significant increase in the efficiency index, growth index and solvency index. Net income increased 1,344.29% from $21.9 to $316.3, earnings per share increased from $0.0004 to $0.0054, and operating cash flow increased 955.74% from $24.4 to $257.6.
C
Hold
3/30/2017Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 3/30/2017 due to a decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 3/30/2017 due to a decline in the total return index.
C
Hold
1/31/2017Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 1/31/2017 due to an increase in the total return index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 1/31/2017 due to an increase in the total return index.
C
Hold
1/11/2017Downgrade
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 1/11/2017 due to a decline in the total return index.
NexgenRx Inc. (NXG.V) was downgraded to C- from C on 1/11/2017 due to a decline in the total return index.
C
Hold
12/27/2016Upgraded
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 12/27/2016 due to a major increase in the total return index and volatility index.
NexgenRx Inc. (NXG.V) was upgraded to C from C- on 12/27/2016 due to a major increase in the total return index and volatility index.
C
Hold
11/25/2016Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to C- from D on 11/25/2016 due to a significant increase in the valuation index, total return index and volatility index.
NexgenRx, Inc. (NXG.V) was upgraded to C- from D on 11/25/2016 due to a significant increase in the valuation index, total return index and volatility index.
D
Sell
11/16/2016Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to D from D- on 11/16/2016 due to a large increase in the total return index, efficiency index and volatility index. Total capital increased 2.61% from $187.8 to $192.7.
NexgenRx, Inc. (NXG.V) was upgraded to D from D- on 11/16/2016 due to a large increase in the total return index, efficiency index and volatility index. Total capital increased 2.61% from $187.8 to $192.7.
D
Sell
4/27/2016Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to D- from D on 4/27/2016 due to a major decline in the volatility index, efficiency index and solvency index.
NexgenRx, Inc. (NXG.V) was downgraded to D- from D on 4/27/2016 due to a major decline in the volatility index, efficiency index and solvency index.
D
Sell
8/20/2015Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to D from D+ on 8/20/2015 due to a decline in the valuation index and growth index. EBIT declined 346.62% from $29.6 to -$73, operating cash flow declined 91.15% from $157 to $13.9, and total revenue declined 1.54% from $968 to $953.1.
NexgenRx, Inc. (NXG.V) was downgraded to D from D+ on 8/20/2015 due to a decline in the valuation index and growth index. EBIT declined 346.62% from $29.6 to -$73, operating cash flow declined 91.15% from $157 to $13.9, and total revenue declined 1.54% from $968 to $953.1.
D
Sell
7/20/2015Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to D+ from D on 7/20/2015 due to a noticeable increase in the growth index, volatility index and valuation index. Total revenue increased 0.66% from $961.7 to $968.
NexgenRx, Inc. (NXG.V) was upgraded to D+ from D on 7/20/2015 due to a noticeable increase in the growth index, volatility index and valuation index. Total revenue increased 0.66% from $961.7 to $968.
D
Sell
11/24/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to D from C- on 11/24/2014 due to a significant decline in the efficiency index, growth index and total return index. Total capital declined 52.4% from $362.6 to $172.6, and total revenue declined 5.4% from $985.8 to $932.6.
NexgenRx, Inc. (NXG.V) was downgraded to D from C- on 11/24/2014 due to a significant decline in the efficiency index, growth index and total return index. Total capital declined 52.4% from $362.6 to $172.6, and total revenue declined 5.4% from $985.8 to $932.6.
C
Hold
8/29/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to C- from C+ on 8/29/2014 due to a major decline in the valuation index, growth index and efficiency index. Operating cash flow declined 96% from -$139.9 to -$5.6, and total capital declined 21.16% from $459.9 to $362.6.
NexgenRx, Inc. (NXG.V) was downgraded to C- from C+ on 8/29/2014 due to a major decline in the valuation index, growth index and efficiency index. Operating cash flow declined 96% from -$139.9 to -$5.6, and total capital declined 21.16% from $459.9 to $362.6.
C
Hold
8/26/2014Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 8/26/2014 due to an increase in the valuation index.
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 8/26/2014 due to an increase in the valuation index.
C
Hold
8/6/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 8/6/2014 due to a decline in the volatility index and total return index.
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 8/6/2014 due to a decline in the volatility index and total return index.
C
Hold
7/22/2014Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 7/22/2014 due to an increase in the valuation index.
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 7/22/2014 due to an increase in the valuation index.
C
Hold
7/7/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 7/7/2014 due to a decline in the volatility index.
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 7/7/2014 due to a decline in the volatility index.
C
Hold
6/17/2014Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 6/17/2014 due to an increase in the volatility index.
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 6/17/2014 due to an increase in the volatility index.
C
Hold
6/2/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 6/2/2014 due to a significant decline in the valuation index, growth index and solvency index. EBIT declined 324.27% from $10.3 to -$23.1, operating cash flow declined 244.82% from $96.6 to -$139.9, and total revenue declined 13.86% from $1.09M to $937.3.
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 6/2/2014 due to a significant decline in the valuation index, growth index and solvency index. EBIT declined 324.27% from $10.3 to -$23.1, operating cash flow declined 244.82% from $96.6 to -$139.9, and total revenue declined 13.86% from $1.09M to $937.3.
C
Hold
5/27/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to C+ from B on 5/27/2014 due to a major decline in the volatility index.
NexgenRx, Inc. (NXG.V) was downgraded to C+ from B on 5/27/2014 due to a major decline in the volatility index.
B
Buy
5/23/2014Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to B from B- on 5/23/2014 due to an increase in the volatility index.
NexgenRx, Inc. (NXG.V) was upgraded to B from B- on 5/23/2014 due to an increase in the volatility index.
B
Buy
5/12/2014Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to B- from C+ on 5/12/2014 due to a large increase in the volatility index.
NexgenRx, Inc. (NXG.V) was upgraded to B- from C+ on 5/12/2014 due to a large increase in the volatility index.
C
Hold
4/22/2014Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 4/22/2014 due to an increase in the total return index, volatility index and valuation index.
NexgenRx, Inc. (NXG.V) was upgraded to C+ from C on 4/22/2014 due to an increase in the total return index, volatility index and valuation index.
C
Hold
4/7/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 4/7/2014 due to a decline in the volatility index and total return index.
NexgenRx, Inc. (NXG.V) was downgraded to C from C+ on 4/7/2014 due to a decline in the volatility index and total return index.
C
Hold
4/3/2014Downgrade
NexgenRx, Inc. (NXG.V) was downgraded to C+ from B on 4/3/2014 due to a significant decline in the efficiency index, valuation index and volatility index. Net income declined 110.65% from $124.9 to -$13.3.
NexgenRx, Inc. (NXG.V) was downgraded to C+ from B on 4/3/2014 due to a significant decline in the efficiency index, valuation index and volatility index. Net income declined 110.65% from $124.9 to -$13.3.
B
Buy
3/13/2014Upgraded
NexgenRx, Inc. (NXG.V) was upgraded to B from C+ on 3/13/2014 due to a noticeable increase in the volatility index, valuation index and total return index.
NexgenRx, Inc. (NXG.V) was upgraded to B from C+ on 3/13/2014 due to a noticeable increase in the volatility index, valuation index and total return index.
